One2Treat launches original treatment-decision approach to clinical research

By Liza Laws

- Last updated on GMT

© Marc Buyse founder and Sebastien Coppe CEO, One2Treat
© Marc Buyse founder and Sebastien Coppe CEO, One2Treat

Related tags Research Clinical trials Data management trial design Patient recruitment

Today (March 26) One2Treat, a progressive startup specializing in digital health solutions, has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.

By integrating various patient-centric outcomes into a single treatment assessment, One2Treat aims to accelerate the delivery of new treatments to the market while reducing trial sample sizes.

Traditional clinical studies often focus on a limited number of primary endpoints, neglecting valuable data and failing to capture the full impact of treatments on patients' lives.

One2Treat's innovative methodology addresses this issue by incorporating all key patient-relevant outcomes into the primary analysis, marking a significant paradigm shift in clinical trial design and analysis.

Marc Buyse is a leading figure in clinical research, renowned for founding IDDI and CluePoints. With decades of academic experience, he has led innovative methodologies for personalized medicine, meta-analysis, and surrogate endpoints. Marc's expertise in biostatistics has driven advancements in data-driven decision-making, patient-centric trial designs and regulatory submissions.

As the founder of One2Treat, he continues to lead innovation in clinical research methodologies and technologies, focusing on SaaS solutions for trial design and analysis while prioritizing patients' needs and clinical relevance at the forefront of every discussion and decision.

He said: “We recognize the importance of listening to patients' preferences and evaluating treatment effects across multiple dimensions.

“Our approach allows sponsors to conduct more patient-centric treatment analysis, resulting in a higher statistical significance and/or a reduced sample size.”

The core of One2Treat's offering lies in its unique blend of statistical methodology, software, and expert clinical insights. By using the seminal Generalized Pairwise Comparisons (GPC) methodology, One2Treat's customized software enables sponsors to analyze data about overall treatment effects comprehensively, providing a comprehensive benefit-risk evaluation based on what matters most to patients.

Sebastien Coppe brings extensive experience in clinical trials and artificial intelligence. Over more than a decade at N-SIDE, he played a pivotal role in leading the company's Life Sciences activities, contributing significantly to its growth from a small start-up to a purpose-driven organization with over 200 employees.

With a deep understanding of the biopharma industry's challenges and opportunities, Sebastien made the bold decision to join Marc Buyse in his latest venture, aiming to industrialize his paradigm-shifting solution enhancing treatment decisions. Sebastien is driven by a strong conviction in the potential of innovative digital solutions to meet the overall patients’ needs and accelerate clinical research timelines. He is committed to pioneering approaches that prioritize patient-centricity and enhance biopharma productivity.

He said: “We are committed to revolutionizing clinical research practices and facilitating a more transparent and efficient transition from drug development to market access.

“Our unique solution not only enhances trial design and analysis but also empowers patients to voice their treatment preferences and access personalized care tailored to their specific needs.”

As One2Treat emerges to disrupt the status quo in both clinical research and market access, it says its vision ‘transcends traditional stakeholders to include clinicians and patients’. Through its dedicated solution, One2Treat says it aims to empower individuals to voice their treatment preferences and access personalized care tailored to their unique specific needs.

In a joint interview, Marc Buyse and Sebastien Coppe shed light on the company's origins and future goals.

OSP​: How did the company come about?

Sebastien​: Marc Buyse has long been driven by a singular vision: to revolutionize clinical research by prioritizing patients' overall priorities in the assessment of treatment effects. Encouraged by positive feedback from collaborations with leading biopharma sponsors, he assembled a team of experts to develop proprietary, patented software, addressing this pressing industry need.

OSP:​ What problem will One2Treat solve within the industry?

Marc:​ One2Treat addresses a critical gap in the industry by championing a more comprehensive approach to evaluating treatment effects. By integrating all key patient-relevant outcomes into a single assessment of the Net Treatment Benefit, One2Treat ensures that clinical trials capture the full spectrum of treatment impacts.

OSP:​ What results are you looking forward to seeing?

Sebastien:​ One2Treat’s goal is to integrate our team's intelligence within a software that will help sponsors incorporate all key outcomes that matter to patients in a single treatment assessment, while scaling the added value to more and more clinical trial designs.

OSP:​ How has your joint expertise added value to One2Treat?

Marc:​ In addition to his extensive expertise in the clinical research industry, Sebastien brings a strong entrepreneurial mindset that complements my scientific approach. Both Sebastien and I share a deep commitment to improving patient outcomes and a proactive attitude towards driving change. This shared dedication ensures that One2Treat remains unwavering in its mission to revolutionize treatment decisions for both trial designs, analysis, and market access questions.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us